Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.43 |
| ▸ | FASN | P49327 | 4/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032 | 0.91 | HDAC2 (0.48) | NPY5RHDAC2FASNHDAC1MGLL | |
| SCHEMBL4030 | 0.91 | HDAC2 (0.48) | NPY5RHDAC2FASNHDAC1MGLL | |
| SCHEMBL12076614 | 0.86 | PTGER4 (0.46) | PTGER4CHRM3 | |
| SCHEMBL11908275 | 0.86 | PTGER4 (0.46) | PTGER4CHRM3 | |
| SCHEMBL12076494 | 0.86 | LIPC (0.48) | PTGER4GAA | |
| SCHEMBL10580 | 0.86 | LIPC (0.48) | PTGER4GAA | |
| SCHEMBL6060 | 0.84 | FASN (0.44) | FASNPTGER4GAA | |
| SCHEMBL10321 | 0.84 | ALDH1A1 (0.48) | FASNPTGER4 | |
| SCHEMBL6062 | 0.84 | FASN (0.44) | FASNPTGER4GAA | |
| SCHEMBL10298 | 0.83 | F10 (0.41) | HDAC2FASNHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | NPY5R 4671/4885HDAC2 417/4885FASN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.